Patents by Inventor Jean-Pierre Cabaniols
Jean-Pierre Cabaniols has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026376Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA, or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism.Type: ApplicationFiled: October 4, 2023Publication date: January 25, 2024Applicant: CELLECTISInventors: Laurent POIROT, David SOURDIVE, Philippe DUCHATEAU, Jean-Pierre CABANIOLS
-
Patent number: 11820996Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism.Type: GrantFiled: September 21, 2018Date of Patent: November 21, 2023Assignee: CELLECTISInventors: Laurent Poirot, David Sourdive, Philippe Duchateau, Jean-Pierre Cabaniols
-
Publication number: 20230287454Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.Type: ApplicationFiled: April 19, 2023Publication date: September 14, 2023Inventors: Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
-
Publication number: 20230228739Abstract: The invention relates to a new potency assay for characterizing the quality and activity of an immune cell expressing a chimeric antigen receptor, the kit to carry out this assay and uses thereof.Type: ApplicationFiled: July 2, 2021Publication date: July 20, 2023Inventors: Xenia NAJ, Anne-Sophie Petit, Roman Galetto, Jean-Pierre Cabaniols
-
Patent number: 11674155Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.Type: GrantFiled: August 5, 2022Date of Patent: June 13, 2023Assignee: CELLECTISInventors: Jean-Pierre Cabaniols, Jean-Charles Epinat, Philippe Duchateau
-
Publication number: 20230087122Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.Type: ApplicationFiled: August 5, 2022Publication date: March 23, 2023Inventors: Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
-
Patent number: 11466291Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.Type: GrantFiled: June 30, 2017Date of Patent: October 11, 2022Assignee: CELLECTISInventors: Jean-Pierre Cabaniols, Jean-Charles Epinat, Philippe Duchateau
-
Patent number: 11186824Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.Type: GrantFiled: March 11, 2016Date of Patent: November 30, 2021Assignee: CELLECTISInventors: Philippe Duchateau, Jean-Pierre Cabaniols, Julien Valton, Laurent Poirot
-
Publication number: 20200208174Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient,for their subsequent use in therapeutic treatments.Type: ApplicationFiled: June 30, 2017Publication date: July 2, 2020Inventors: Jean-Pierre CABANIOLS, Jean-Charles EPINAT, Philippe DUCHATEAU
-
Publication number: 20190010514Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding H2M and/or CIITA or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism.Type: ApplicationFiled: September 21, 2018Publication date: January 10, 2019Applicant: CELLECTISInventors: Laurent POIROT, David SOURDIVE, Philippe DUCHATEAU, Jean-Pierre CABANIOLS
-
Publication number: 20180291343Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.Type: ApplicationFiled: March 11, 2016Publication date: October 11, 2018Applicant: CellectisInventors: Philippe DUCHATEAU, Jean-Pierre CABANIOLS, Julien VALTON, Laurent POIROT
-
Publication number: 20180171298Abstract: The present invention relates to methods for improving therapeutic activity of NK cell, such as their cytotoxic/cytolytic activity, to be used in immunotherapy, by gene editing. In particular, these methods comprise a step of reduction or inactivation of gene expression using specific endonuclease such as TAL-nuclease, CRISPR or Argonaute. An additional genetic modification can be performed by (over)expressing at least one gene involved in N K function. The present invention encompasses also engineered NK cell, pharmaceutical composition containing the same.Type: ApplicationFiled: June 30, 2016Publication date: June 21, 2018Inventors: Philippe DUCHATEAU, Jean-Pierre CABANIOLS, Julien VALTON
-
Publication number: 20170016025Abstract: The present invention pertains to engineered T-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered T-cells of the invention are characterized in that the expression of beta 2-microglobulin (B2M) and/or class II major histocompatibility complex transactivator (CIITA) is inhibited, e.g., by using rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding B2M and/or CIITA, or by using nucleic acid molecules which inhibit the expression of B2M and/or CIITA. In order to further render the T-cell non-alloreactive, at least one gene encoding a component of the T-cell receptor is inactivated, e.g., by using a rare-cutting endonucleases able to selectively inactivating by DNA cleavage the gene encoding said TCR component. In addition, expression of immunosuppressive polypeptide can be performed on those modified T-cells in order to prolong the survival of these modified T cells in host organism.Type: ApplicationFiled: March 11, 2015Publication date: January 19, 2017Inventors: Laurent POIROT, David SOURDIVE, Philippe DUCHATEAU, Jean-Pierre CABANIOLS
-
Publication number: 20160273003Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.Type: ApplicationFiled: March 24, 2016Publication date: September 22, 2016Inventors: Philippe DUCHATEAU, Christophe PEREZ, Sylvia BRUNEAU, Jean-Pierre CABANIOLS, Julianne SMITH, Agnes GOUBLE
-
Patent number: 9365864Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.Type: GrantFiled: May 22, 2013Date of Patent: June 14, 2016Assignee: CELLECTISInventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
-
Publication number: 20140121115Abstract: New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.Type: ApplicationFiled: December 21, 2012Publication date: May 1, 2014Applicant: CellectisInventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, Andre Choulika, Phillipe Duchateau, Jean-Charles Epinat, Agnes Gouble, Emmanuel Lacroix, Frederic Paques, Christophe Perez-Michaut, Julianne Smith, Davie Sourdive
-
Publication number: 20140004608Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.Type: ApplicationFiled: May 22, 2013Publication date: January 2, 2014Applicant: CELLECTISInventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
-
Patent number: 8476072Abstract: The invention relates to a set of genetic constructs which allow the efficient and reproducible introduction of a specific nucleotide sequence at a fixed position in the genome by generating a double strand break at a specific position in the genome using a meganuclease and so stimulating a homologous recombination event at this locus between the genomic site and a transfected donor sequence. The present invention also relates to methods using these constructs and to these materials in the form of a kit.Type: GrantFiled: October 23, 2009Date of Patent: July 2, 2013Assignee: CellectisInventors: Jean-Pierre Cabaniols, Andre Choulika, Christophe Delenda
-
Publication number: 20130045539Abstract: The invention relates to a set of genetic constructs which comprises at least a first recombinogenic construct (i) with at least two portions homologous to the genomic regions preceding and following the DNA target site of a site specific endonuclease and also comprising both a negative selection and positive selection mark interposed with the homologous portions as well as a region into which a sequence of interest can be cloned adjacent to the positive selection marker; and a second construct (ii, iii or iv) comprising the meganuclease. The present invention also relates to a kit comprising these constructs and methods to use this set of constructs to introduce into the genome of a target cell, tissue or organism a sequence of interest.Type: ApplicationFiled: February 18, 2011Publication date: February 21, 2013Applicant: CELLECTISInventors: Christophe Delenda, Jean-Pierre Cabaniols
-
Publication number: 20120159659Abstract: New rare-cutting endonucleases, also called custom-made meganucleases, which recognize and cleave a specific nucleotide sequence, derived polynucleotide sequences, recombinant vector cell, animal, or plant comprising said polynucleotide sequences, process for producing said rare-cutting endonucleases and any use thereof, more particularly, for genetic engineering, antiviral therapy and gene therapy.Type: ApplicationFiled: September 28, 2010Publication date: June 21, 2012Inventors: Sylvain Arnould, Sylvia Bruneau, Jean-Pierre Cabaniols, Patrick Chames, André Choulika, Philippe Duchateau, Jean-Pierre Epinat, Agnès Gouble, Emmanuel Lacroix, Frédéric Paques, Christophe Perez-Michaut, Julianne Smith, David Sourdive